Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409569 | 0.92 | ITGB3 (0.54) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL7417991 | 0.89 | ITGB3 (0.55) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7415207 | 0.88 | ITGB3 (0.50) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7414434 | 0.85 | F2 (0.42) | ITGB3ITGA2BF2TMPRSS6 | |
| SCHEMBL7415975 | 0.85 | ITGB3 (0.59) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7417592 | 0.85 | ITGB3 (0.49) | ITGB3ITGA2BITGAVF2TMPRSS6 | |
| SCHEMBL7416602 | 0.85 | ITGB3 (0.38) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7415327 | 0.85 | ITGB1 (0.42) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7415235 | 0.84 | KCNA5 (0.44) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7417563 | 0.84 | ITGB3 (0.39) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |